Cancer Research Highlight: Puma Biotech's Basket Pays Off [Seeking Alpha]
Puma Biotechnology Inc (PBYI)
Last puma biotechnology inc earnings: 2/20 04:07 pm
Check Earnings Report
US:NYSE Investor Relations:
pumabiotechnology.com/ir.html
Company Research
Source: Seeking Alpha
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you're interested in this service, you can try a free two-week trial today! Puma Biotechnology ( PBYI ) has made its entire game up on the back of one drug, a pan-HER inhibitor called neratinib (branded Nerlynx). It offers a unique proposition from the more commonly used HER2 therapies marketed by Roche ( OTCQX:RHHBY ), such as Herceptin, because it is given as pills. This opens up the possibility of continuous therapy, and we saw this realized with an approval in the extended adjuvant setting of patients with HER2-positive breast cancer last year. Earlier this year, PBYI scored a coup when it was able to reverse the decision by the EMA to not allow its drug to reach market in the EU. Now, neratinib is available
Show less
Read more
Impact Snapshot
Event Time:
PBYI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBYI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBYI alerts
High impacting Puma Biotechnology Inc news events
Weekly update
A roundup of the hottest topics
PBYI
News
- Do Puma Biotechnology's (NASDAQ:PBYI) Earnings Warrant Your Attention? [Yahoo! Finance]Yahoo! Finance
- Puma Biotech cleared to trial Takeda-partnered breast cancer therapy in U.S. [Seeking Alpha]Seeking Alpha
- Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast CancerBusiness Wire
- Puma Biotechnology, Inc. (NASDAQ: PBYI) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
PBYI
Earnings
- 2/29/24 - Miss
PBYI
Analyst Actions
- 2/13/24 - HC Wainwright
PBYI
Sec Filings
- 3/19/24 - Form 4
- 3/19/24 - Form 8-K
- 2/29/24 - Form 10-K
- PBYI's page on the SEC website